Retatrutide, a quite new molecule, has elicited significant attention within the medical community due to its anticipated impact on obesity control. Present studies indicate that this dual agonist of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors exhibits promising effects in patient testing, potentially driving